Biotech player PYC Therapeutics (ASX:PYC) has dosed its first patient in a clinical trial seeking to ameliorate symptoms of Autosomal Dominant Optic Atrophy (ADAO). The condition is one which causes blindness and is commonly believed to be passed down from parents to children. For all intents and purposes, the disease is rare. Blindness often occurs in the patients’ twenties according to at least one author; PYC has been developing a drug of interest designed to treat the condition which it estimates affects 1 in 35,000 people. On Friday, the company has officially flagged its commencement of …